Connect with us

Headlines

Pharma Giant Might Sell Eyecare Division

mm

Published

on

A turnaround isn’t progressing as quickly as expected.

The chairman of Novartis says it’s possible the pharmaceutical company will sell Alcon, its eyecare unit.

A planned turnaround at Alcon isn’t progressing as quickly as Novartis officials had hoped, Reuters reports.

Chairman Joerg Reinhardt told the Switzerland-based publication SonntagsZeitung that for the long term, “the question arises as to whether we are the best owner for Alcon.”

Alcon, whose U.S. headquarters are in Texas, makes items including contact care products, ophthalmic pharmaceuticals, dry eye products and ocular vitamins. Novartis took ownership of the company through several deals totaling $51 billion.

Advertisement

Reinhardt said Novartis continues to try to turn the company around. For this quarter, he anticipates Alcon sales being flat, or even down a bit, according to SonntagsZeitung.

According to Reuters, Novartis “has blamed a failure to innovate and inconsistent customer service” for Alcon’s issues.

Read more at Reuters

SPONSORED VIDEO

Sponsored by Shamir

Customer Focused, Service Oriented, Forward Thinking

for life improvement, fashion, performance sports, occupational single vision, and progressive lenses. Our values, the driving force behind our ideas and actions, keep the ECP in the center. Every Shamir representative is personally committed to our customers’ vision, and to providing the best service and support to meet and exceed their expectations, all with a personal touch.

Promoted Headlines

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular